Exact Sciences to Buy Genomic Health for About $2.8 Billion

(Bloomberg) -- Exact Sciences Corp. agreed to buy Genomic Health Inc. in a $2.8 billion cash and stock deal to expand its offering of cancer tests beyond the colon cancer test Cologuard.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.